Navigation Links
Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine Months Ended September 30, 2012 Compared to Same Periods in 2011
Date:10/31/2012

SEATTLE, Nov. 1, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported financial results for the third quarter of 2012 and recent accomplishments.

Financial ResultsThird Quarter Results

For the quarter ended September 30, 2012, total operating expenses were $14.7 million compared to $15.3 million for the same period in 2011. Net loss attributable to common shareholders was $20.2 million ($0.38 per share) for the quarter ended September 30, 2012 compared to a net loss attributable to common shareholders of $29.7 million ($0.80 per share) for the same period in 2011. The decrease in net loss attributable to CTI's common shareholders is primarily due to a decrease in non-cash deemed dividends on preferred stock issuances. The decline in dividends and deemed dividends on preferred stock between the comparable periods is attributable to the total dollar amounts of the equity offerings completed.

Nine-Month Results

For the nine months ended September 30, 2012, total operating expenses were $82.2 million compared to $52.3 million for the same period in 2011. Most of the increase in operating expenses is primarily related to the $29.1 million acquired in-process research and development expense related to the acquisition of pacritinib from S*BIO Pte Ltd. in 2012.  Net loss attributable to common shareholders was $96.2 million ($2.12 per share) for the nine months ended September 30, 2012 compared to a net loss attributable to common shareholders of $103.2 million ($3.11 per share) for the same period in 2011. The decrease in net loss attributable to CTI's common shareholders is primarily due to a decrease in non-cash deemed dividends on preferred stock issuances. The decline in dividends and deemed dividends on preferred stock between the comparable periods is attrib
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Clinical Study: Dietary Supplement SagaPro Reduces Frequent Urination
6. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
7. BioElectronics ActiPatch Reduces Muscle Soreness in Runners
8. Solos Endoscopy Reduces Liabilities by More than $570,000
9. Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women
10. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
11. Hanger Reports Earnings of $0.50 Per Diluted Share for the Third Quarter 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ... composition, including reductions in body fat content and ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, ... leading innovator of less invasive, miniaturized circulatory support ... heart failure, today announced that it expects revenues ... approximately $53 million, bringing expected full-year 2013 revenues ... revenue growth of 87% for 2013 above 2012 ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... event for buyers and sellers of high-value chemistry, will ... conference at the Miami Beach ... http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) More than 3,500 attendees ... will take part in the conference, which includes on-site ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Echo Therapeutics, Inc. (Nasdaq: ECTE ), ... non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and ... results for the third quarter and nine months ended ... is available through Echo,s website at www.echotx.com . ...
... Fla., Nov. 8, 2011 VR Laboratories LLC ... as chief scientific advisor.  Rothman will head scientific ... manufacture and bring to market world-class botanical consumer, ... foreign and domestic markets. In addition to assisting ...
Cached Medicine Technology:Echo Therapeutics Announces Third Quarter 2011 Financial Results 2Echo Therapeutics Announces Third Quarter 2011 Financial Results 3Echo Therapeutics Announces Third Quarter 2011 Financial Results 4Echo Therapeutics Announces Third Quarter 2011 Financial Results 5James Rothman Named Chief Scientific Advisor at VR Laboratories 2James Rothman Named Chief Scientific Advisor at VR Laboratories 3James Rothman Named Chief Scientific Advisor at VR Laboratories 4
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Quality Act, Would Save Thousands of Lives,Billions of Dollars, ... joined forces Wednesday, April 2, 2008, with U.S.,Senate health ... Health Care,Quality Act," a measure to bring the power ... view the Multimedia News Release, go to:, http://www.prnewswire.com/mnr/brt/32565/ , ...
... Top of Medical ... Coverage, CHARLOTTE, N.C., April ... care and insurance benefits should be,a much easier task for the bank,s associates ... costs, and give,associates more flexibility in the way they choose and pay for ...
... Opportunity to Emerging Hip-Hop ... Talent, NEW ... TAG brand announce the formation of a new,hip-hop record label, TAG Records. The ... president of the New York-based,venture. As president, Dupri will set the creative vision ...
... ISTA,Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... United States Attorney,s Office in Buffalo requesting the,production ... to Xibrom(TM) (bromfenac sodium ophthalmic solution),0.09%., It ... applicable U.S. and,foreign laws, rules and regulations of ...
... Like horses running down the long stretch of a ... neck-and-neck when it comes to preventing stroke among people with ... years, patients who had a minimally-invasive procedure were just as ... die, as those who had open-neck surgery. , The findings ...
... Efforts to Safeguard Sight, Promote Healthy Vision ... for Children and Expand Access to Care, ... recognized for providing important leadership on health care,policy issues by ... 34,000 member American Optometric Association (AOA).,Optometrists in West Virginia and ...
Cached Medicine News:Health News:Video: Senators and CEOs Urge Passage of Health IT Bill Now 2Health News:Video: Senators and CEOs Urge Passage of Health IT Bill Now 3Health News:Bank of America Launches Innovative Approach to Managing Health Care 2Health News:Bank of America Launches Innovative Approach to Managing Health Care 3Health News:Bank of America Launches Innovative Approach to Managing Health Care 4Health News:Jermaine Dupri and Island Def Jam Music Group Launch New Hip-Hop Label in Partnership with TAG Body Sprays 2Health News:Jermaine Dupri and Island Def Jam Music Group Launch New Hip-Hop Label in Partnership with TAG Body Sprays 3Health News:ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM) 2Health News:ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM) 3Health News:It's neck-and-neck down the long stretch for 2 stroke-prevention procedures 2Health News:It's neck-and-neck down the long stretch for 2 stroke-prevention procedures 3Health News:It's neck-and-neck down the long stretch for 2 stroke-prevention procedures 4Health News:Sen. Robert Byrd Receives AOA Health Care Leadership Award 2
... Iodine 'Prep' solutions are ... mucous membrane preparation prior ... Povidone Iodine 'Scrub' solutions ... surfactants. Each is effective ...
Triad Plus PVP-I Scrub Solution has broad-spectrum germicidal action.This special formula is designed to help break down body oils and yet limit the bubbles the surfactants allowing easy removal and ...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
... are designed for individual application and are ... in nursing homes, home healthcare settings, blood ... hospital departments. This unit dose pouch contains ... germicidal and cleansing agent. Hydrogen Peroxide's chief ...
Medicine Products: